ONCY
What one share of Oncolytics Biotech holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms.
Oncolytics Biotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.34 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.24 |
| Cash and investments | $0.03 |
| Book value | −$0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.30 | $0.00 | −$0.26 | — | $0.04 |
| 2025 | — | −$0.30 | $0.00 | −$0.21 | — | −$0.04 |